CA3189243A1 - Compositions et methodes de soulagement d'affections et de troubles neurologiques - Google Patents

Compositions et methodes de soulagement d'affections et de troubles neurologiques

Info

Publication number
CA3189243A1
CA3189243A1 CA3189243A CA3189243A CA3189243A1 CA 3189243 A1 CA3189243 A1 CA 3189243A1 CA 3189243 A CA3189243 A CA 3189243A CA 3189243 A CA3189243 A CA 3189243A CA 3189243 A1 CA3189243 A1 CA 3189243A1
Authority
CA
Canada
Prior art keywords
agent
pabra
less
dose
blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189243A
Other languages
English (en)
Inventor
Anthony P. FORD
Gabriel VARGAS
Wei Chen
Renee S. MARTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curasen Therapeutics Inc
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of CA3189243A1 publication Critical patent/CA3189243A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computerised tomographs
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/501—Clinical applications involving diagnosis of head, e.g. neuroimaging, craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Selon divers aspects et modes de réalisation, l'invention concerne des compositions et des méthodes permettant d'identifier des patients nécessitant une amélioration de la cognition et/ou de traiter une maladie neurodégénérative affectant un patient, et de traiter un tel patient. Plus spécifiquement, l'invention concerne, dans certains modes de réalisation, l'administration d'un agoniste de ?-AR (tel qu'un agent-?) et d'un ?-bloquant à action périphérique (PABRA) à un patient en ayant besoin.
CA3189243A 2020-09-01 2021-08-31 Compositions et methodes de soulagement d'affections et de troubles neurologiques Pending CA3189243A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US63/073,353 2020-09-01
US202163212077P 2021-06-17 2021-06-17
US63/212,077 2021-06-17
PCT/US2021/048540 WO2022051305A1 (fr) 2020-09-01 2021-08-31 Compositions et méthodes de soulagement d'affections et de troubles neurologiques

Publications (1)

Publication Number Publication Date
CA3189243A1 true CA3189243A1 (fr) 2022-03-10

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189243A Pending CA3189243A1 (fr) 2020-09-01 2021-08-31 Compositions et methodes de soulagement d'affections et de troubles neurologiques

Country Status (8)

Country Link
US (1) US20230263749A1 (fr)
EP (1) EP4208159A1 (fr)
JP (1) JP2023541379A (fr)
KR (1) KR20230107211A (fr)
AU (1) AU2021337583A1 (fr)
CA (1) CA3189243A1 (fr)
MX (1) MX2023002350A (fr)
WO (1) WO2022051305A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240146384A1 (en) 2021-03-03 2024-05-02 Lenovo (Singapore) Pte. Ltd. Beam failure detection using shared reference signals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
JP2021527712A (ja) * 2018-06-14 2021-10-14 キュラセン セラピューティクス インコーポレイテッド 神経系疾患および障害を、診断、監視、および治療するための方法
CN114007615A (zh) * 2019-03-27 2022-02-01 库拉森疗法公司 β肾上腺素能激动剂及其使用方法
CA3153305A1 (fr) * 2019-10-25 2021-04-29 Anthony P. FORD Procedes de traitement de troubles neurologiques avec des agonistes ?<sub>1a</sub>-ar partiels
EP4076422A4 (fr) * 2019-12-18 2024-01-24 Curasen Therapeutics Inc Procédés d'atténuation de maladies et de troubles neurologiques

Also Published As

Publication number Publication date
AU2021337583A1 (en) 2023-05-04
KR20230107211A (ko) 2023-07-14
US20230263749A1 (en) 2023-08-24
EP4208159A1 (fr) 2023-07-12
JP2023541379A (ja) 2023-10-02
WO2022051305A1 (fr) 2022-03-10
MX2023002350A (es) 2023-04-26

Similar Documents

Publication Publication Date Title
US11607395B2 (en) Methods for improving neurological diseases and disorders
US7408079B2 (en) Imaging agents and methods of imaging NAALADase or PSMA
CN116617420A (zh) 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途
US8168800B2 (en) Aβ-binding small molecules
CA3100697A1 (fr) Procedes de diagnostic, de surveillance et de traitement de maladies et de troubles neurologiques
CN109475594A (zh) 用于成像ido1酶的放射性配体
CA3189243A1 (fr) Compositions et methodes de soulagement d&#39;affections et de troubles neurologiques
US20200017445A1 (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US20230414588A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20230157974A1 (en) Compositions and methods for improving neurological diseases and disorders
CA3100848A1 (fr) Procedes d&#39;attenuation de maladies et de troubles neurologiques
CA2911307C (fr) Utilisation de derives fluores de 4-aminopyridine en therapeutique et en imagerie medicale
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
US20210251923A1 (en) Methods for improving neurological diseases and disorders
US20230357154A1 (en) Butyrylcholinesterase compounds and use in diseases of the nervous system
WO2023250332A1 (fr) Compositions et méthodes impliquant des composés isolés
WO2023250334A1 (fr) Compositions et méthodes impliquant des composés isolés
US20160243266A1 (en) Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain
US9610369B2 (en) Compound suitable for detection of vesicular acetylcholine transporter
KR20170138437A (ko) 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물